Stock Events

Stock Events

Marker Therapeutics 

€1.45
0
+€0.23+18.85% Friday 06:05

Statistics

Day High
1.45
Day Low
1.45
52W High
1.86
52W Low
0.72
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q4 2025
Next
-0.17
-0.14
-0.11
-0.09
Expected EPS
-0.1568963814
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GX1.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR T-cell therapies, competing in the broader cell therapy space for cancer.
Novartis
NVS
Mkt Cap297.35B
Novartis is a major player in the cell therapy space with its approved CAR-T cell therapy, Kymriah, competing in the oncology market.
Allogene Therapeutics
ALLO
Mkt Cap663.08M
Allogene Therapeutics is focused on the development of allogeneic CAR-T (off-the-shelf) therapies, competing in the cell therapy space for cancer.
Precigen
PGEN
Mkt Cap1.47B
Precigen is a biotechnology company that develops CAR-T and other gene and cell therapies, competing in the same space as Marker.
Sangamo Therapeutics
SGMO
Mkt Cap104.07M
Sangamo Therapeutics works on gene editing and gene therapy, including CAR-Treg therapies, which could compete in the broader market of cell therapies for cancer.

About

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Show more...
CEO
Dr. Juan F. Vera M.D.
Employees
5
Country
Germany
ISIN
US57055L2060

Listings

MU
DE
GX1.MU
F
DE
GX1.F
XNAS
US
MRKR
BOATS
BOATS
MRKR.BOATS

0 Comments

Share your thoughts

FAQ

What is Marker Therapeutics stock price today?▼
The current price of GX1.MU is €1.45 EUR — it has increased by +18.85% in the past 24 hours. Watch Marker Therapeutics stock price performance more closely on the chart.
What is Marker Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Marker Therapeutics stocks are traded under the ticker GX1.MU.
Is Marker Therapeutics stock price growing?▼
GX1.MU stock has risen by +22.88% compared to the previous week, the month change is a +18.85% rise, over the last year Marker Therapeutics has showed a +39.42% increase.
When is the next Marker Therapeutics earnings date?▼
Marker Therapeutics is going to release the next earnings report on May 20, 2026.
What were Marker Therapeutics earnings last quarter?▼
GX1.MU earnings for the last quarter are -0.09 EUR per share, whereas the estimation was -0.17 EUR resulting in a +47.58% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Marker Therapeutics have?▼
As of April 14, 2026, the company has 5 employees.
In which sector is Marker Therapeutics located?▼
Marker Therapeutics operates in the Other sector.
When did Marker Therapeutics complete a stock split?▼
Marker Therapeutics has not had any recent stock splits.
Where is Marker Therapeutics headquartered?▼
Marker Therapeutics is headquartered in Houston, Germany.